Jun 23, 2021 / 02:00PM GMT
Steve Seedhouse - Raymond James Financial - Analyst
Well, good morning and welcome, everyone, to the next session at the Raymond James Human Health Innovation Conference. I am Steve Seedhouse. It really is a pleasure for me to welcome the next participating company at our conference, InflaRx. InflaRx is a biotech company developing an anti-C5a antibody, vilobelimab or IFX-1, formally for inflammatory immune disorders. And I'm joined by, of course, CEO, Niels Riedemann; and Chief Strategy Officer, Jordan Zwick; and really looking forward to our virtual fireside chat.
So I would just also mention that listeners are invited to submit questions if you'd like via OpenExchange or you can email me directly.
Questions and Answers:
Steve Seedhouse - Raymond James Financial - AnalystBut with that, would like to just hop right into it. And Niels, I wanted to start with your Hidradenitis Suppurativa program. Talk about basically the latest update, which was essentially that the FDA remains committed to HiSCR endpoint, which is what you used in your Phase II
Trustpilot
